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The accumulating data from randomized clinical trials provide the COX‐1 and COX‐2, respectively. The drug is 60-fold more potent to in-
rational to consider the potential role of daily aspirin use in colorectal
cancer (CRC) prevention, and possibly other types of cancer (Thun
et al., 2012). However, some questions require to be addressed before
the recommendation for the prophylactic use of aspirin in the popula-
tion: (i) what is the mechanism of the anti-tumorigenic effect of aspi-
rin?; (ii) is the chemopreventive effect dose-dependent?; (iii) may
daily low-dose aspirin affect other types of cancers in addition to
CRC?; (iv) does the reduced risk of colorectal cancer by daily aspirin
outweigh harm from aspirin-induced bleeding?
In this issue of EBioMedicine, Li et al. (2015) provide novel insights
into the mechanism of action of aspirin in preventing CRC. They ad-
dressed the hypothesis that the drug normalizes the expression of epi-
dermal growth factor receptor (EGFR), a transmembrane receptor
tyrosine kinase of the ErbB family implicated in the etiology of CRC
(Normanno et al., 2006). Moreover, they explored the possibility that
the effect of aspirin was dependent on its capacity to modulate cycloox-
ygenase (COX)-2 expression. The COX enzyme catalyzes the rate-
limiting oxidative and peroxidative enzymatic steps in the biosynthesis
of prostanoids which affect colorectal tumorigenesis via a number of
distinct mechanisms (Patrignani and Patrono, 1851). They studied the
expression levels of colonic EGFR and COX-2, in familial adenomatous
polyposis (FAP) patients, sub-grouped on pathological disease stage,
versus normal individuals. They found that EGFR and COX-2 proteins
were overexpressed as compared to controls in premalignant and ma-
lignant lesions and that the two proteins were colocalized. Mechanistic
studies performed in human colonic epithelial cells as well as in murine
embryonic ﬁbroblasts clearly showed that COX-2 overexpression trig-
gers the activation of the c-Jun-dependent transcription factor, activator
protein-1 (AP-1), which binds to the Egfr promoter, thus leading to
EGFR accumulation. Interestingly, they found that FAP patients who
were classiﬁed as regular aspirin users [if they reported taking two or
more standard (325 mg) aspirin tablets per week within the previous
12 months] showed lower levels of EGFR and also COX-2.
Aspirin (acetylsalicylic acid) belongs to the family of nonsteroidal
anti-inﬂammatory drugs (NSAIDs) which share common therapeutic
and side-effects through the inhibition of COX-1 and COX-2
(Patrignani and Patrono, 1851). Aspirin is the only NSAID which causes
an irreversible inactivation of COX-isozymes through acetylation of
strategically located serine residues, i.e., Ser529 and Ser516 in humanDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.03.019.
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2013). It has a short half-life (~20 min), due to a rapid hydrolysis to
salicylic acid by plasma/tissue esterases and ﬁrst pass hepatic metabo-
lism. Its metabolite salicylic acid has a longer half-life (~2–4.5 h) but is
not an efﬁcient inhibitor of COX‐isozyme activity. Aspirin is adminis-
tered at low-doses (75–100 mg daily) for the prevention of athero-
thrombosis (Patrono et al., 2008). The administration of enteric-coated
aspirin 100 mg/day is associated with systemic plasma concentrations
of acetylsalicylic acid and salicylic acid in the μmolar range (i.e., 4 μM
and 40 μM, respectively) (Patrignani et al., 2014). Daily low-dose aspirin
causes a complete suppression of platelet COX-1 activity which is asso-
ciatedwith saturation of the antiplatelet inhibitory effect (Patrono et al.,
2008; Patrignani et al., 2014). Due to irreversible COX-1 inactivation and
the fact that platelets have limited capacity for de novo protein synthe-
sis, the administration of low-dose aspirin every 24 h causes a complete
and persistent inhibition of COX-1 in platelets associated with a limited
and rapidly reversible inhibitory effect on COX-2 expressed in nucleated
cells (Patrono et al., 2008). Consequently, persistent inhibition of COX-2
activity by aspirin requires the administration of higher and repeated
daily doses (Patrono et al., 2008).
Based on clinical pharmacology data, the administration of two or
more standard (325 mg) aspirin tablets per week used in the study by
Li et al. (2015) seems to be incompatible with an inhibitory effect of
the drug on COX-2-dependent prostanoids produced by nucleated in-
testinal epithelial cells. In contrast, this aspirin administration schedule
might have indirectly down-regulated COX-2 expression in colonic ep-
ithelial cells through the inhibition of platelet function (Thun et al.,
2012). In fact, platelet-derived products may regulate COX-2 induction
in colorectal epithelial cells and stromal cells (Thun et al., 2012).
Li et al. (2015) veriﬁed the possible direct effect of aspirin on COX-2-
dependent EGFR induction by performing experiments using epithelial
cells isolated from intestinal polyps of APCMin/+ mice which express
high levels of COX-2 and EGFR versus and normal epithelial cells. These
cells were treated in vitro with either aspirin (1–4 mM) or the selective
COX-2 inhibitor celecoxib (10–40 μM) and a profound down-regulation
of EGFR protein levels was found only at the highest concentrations of
the two drugs. Differently from the data obtained in FAP patients, where
aspirin was administered in vivo, the drug did not affect COX-2 protein
levels in vitro. It is noteworthy that the concentrations of aspirin and
celecoxib used in vitro were several folds higher than those reached at
therapeutic doses in humans. These results may suggest the role of
COX-independent mechanism in EGFR downregulation detected in vitro
by high concentration of the drugs, plausibly through a direct inhibitory
effect on the activation of AP-1 activity (Dong et al., 1997).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and EGFR. Thus, COX-2 derived prostanoids cause transactivation of the
EGFR kinase cascade in colon cancer cells (Pai et al., 2002) whereas the
activation of EGFR can stimulate COX-2 biosynthesis (Coffey et al.,
1997). The study by Li et al. (2015) reveals a novel functional association
between COX-2 and EGFR during colorectal carcinogenesis, and pro-
vides the rational for aspirin as an adjuvant treatment to improve the ef-
ﬁcacy of EGFR inhibitors in CRC. Clinical studies should be performed to
verify whether the coadministration of low-dose aspirin and possibly
other antiplatelet agents, such as P2Y12 antagonists, may lead to over-
come the resistance to EGFR inhibitors in cancer treatment.
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